about
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneCoinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunityRole of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsB7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host diseaseCell surface signaling molecules in the control of immune responses: a tide model.Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactionsMechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.Control of autoimmune diseases by the B7-CD28 family molecules.From the guest editor: Tumor site immune modulation therapy.PD-1 as an immune modulatory receptor.Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.Consensus nomenclature for CD8(+) T cell phenotypes in cancerPD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell KillingCD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotypeAnti-PD-1/PD-L1 therapy of human cancer: past, present, and future.The many sounds of T lymphocyte silence.Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis.Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEMB7-H4-deficient mice display augmented neutrophil-mediated innate immunity.Fine tuning the immune response through B7-H3 and B7-H4The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitopeCD137 as a biomarker for tumor-reactive T cells: finding gold in the desert.Costimulation of T cells for tumor immunity.Costimulation of T-cell-mediated tumor immunity.Predictors of responses to immune checkpoint blockade in advanced melanomaProgrammed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.Antibody gene therapy: old wine in a new bottle.Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules.Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.Turning the tide of lymphocyte costimulation.PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells.Dendritic cell-associated B7-H3 suppresses the production of autoantibodies and renal inflammation in a mouse model of systemic lupus erythematosusCharacterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinomaB7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse modelsB7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cellsCD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers
P50
Q28131654-37DF94C2-23D8-4CB4-A979-A12A86F4F9B2Q28553703-BE6FFBD0-75AC-419F-854F-DD5EAC30B9D6Q34415743-593FA8CB-3983-4A67-BB59-AEA52DE422EAQ34578170-D1B93D3C-C96F-46B5-B67F-8CB38471186FQ34810629-F23E962D-6A32-404A-A9D2-508EA1B79050Q35223235-01542F91-0AA8-44E4-A4B8-57EBD5D6B327Q35422283-90968A77-A34A-4521-BA6A-F1938809A091Q35613336-D4993A50-0546-4849-8475-931CF0041216Q35644278-C2619EE8-31B3-4A52-868E-D8796722FEBDQ35673195-AC73D03A-6E5C-4BBE-B61C-87EF35B28F7FQ35681585-B71889F0-FACB-4A61-B167-DA8F4F3B9B71Q35764479-545320F4-9D0C-4825-A47F-AB2C5DF4A1B8Q35798822-E28E7182-D4A3-4CA3-9940-BCF8D8870D7DQ35814368-A8122E72-2E1C-416A-B903-6AA24034F371Q35828831-58D5A2B2-21D1-488D-B62B-BB75FD37651DQ36106006-D4B2B734-73E8-4A40-B948-B0FEC0482811Q36290302-BEC36FE0-2322-4A3F-869D-D4FE57ADD973Q36413093-285E572A-10D8-466A-A92C-DBB50B921818Q36802430-2D381810-DD01-4B94-A5B8-A2ED7855ED08Q36839780-41C752EF-B7A0-4334-B704-238501B1C51DQ37109394-850DE433-3B6A-4887-BAA5-CD104C003D08Q37227080-E69C6D87-9F81-4F89-A947-2E683102B3B7Q37728225-4F9226F1-3318-462E-96A0-C34FAB929BE5Q39631391-780D5515-CF52-4A73-86FB-8CB8AC7E0D2FQ40385129-22E5C14E-9484-4267-8F1F-24F38322C56CQ41079242-466C12E7-2EA4-4771-A3A7-E2579C9A70FBQ41701241-476C550E-3AC0-4CCF-9C87-2BD9EDB5B99DQ42463266-A5D112AB-596A-4D25-84F9-5FA5960C203CQ42962305-F3F86227-85BC-4B01-94E3-3BBA0FFC9E5FQ45884686-59562882-1BF5-4E92-9723-9A2EF882BB55Q47769393-404954BF-3586-4E49-9511-DA5B0D7FE67BQ50205430-D79AEE83-5DAB-4588-A910-994E3DC3093FQ51807560-FFFE5910-391B-4255-85A4-5B0E341EF114Q53488547-A7F0CEA5-9977-4229-99B5-83B96B460E44Q54378086-9035AED9-BD02-49B9-AE0B-557B533B3236Q64051822-3530F694-539B-4FB6-A860-8651882F24EFQ73311425-A9DDBDA6-9751-46D0-8535-F9870555C99CQ89457607-AF71CD44-0EE1-4CB4-B32E-C7F8E1F008EDQ90685618-1FC74A90-B397-42B0-B9C4-A04F942C9ED8Q91324160-BA9DDDC1-B867-42A2-9EDD-F1638873ADA6
P50
description
cancer researcher at Yale School of Medicine
@en
wetenschapper
@nl
name
L Chen
@ast
L Chen
@nl
Lieping Chen
@en
Lieping Chen
@es
type
label
L Chen
@ast
L Chen
@nl
Lieping Chen
@en
Lieping Chen
@es
prefLabel
L Chen
@ast
L Chen
@nl
Lieping Chen
@en
Lieping Chen
@es
P108
P106
P1153
57193328845
P31
P496
0000-0002-6825-3069